URL has been copied successfully!
Eli Lilly and Company (NYSE:LLY) is facing growing pressure from India’s fast-expanding generics market. Lower-cost versions of its blockbuster drugs are weighing on the company’s sales, with the most significant impact seen in its diabetes and weight-loss drug Mounjaro.
Mounjaro Losing Its Exclusivity
Mounjaro, which was previously a top-selling drug, is now facing headwinds as competitors enter the market, according to a report by Bloomberg. Its sales dropped to $12.3 million in March from $14.6 million a month earlier, per Pharmarack data.
The decline came amid the launch of multiple cheaper alternatives that mimic the effects of Lilly’s therapies. This has eroded Lilly’s market share among cost-conscious patients and intensified …
Please follow us:
This post was originally published here
